Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Meeting ReportOncology: Basic, Translational & Therapy

Preclinical evaluation of anti-cadherin 3 human-mouse chimeric monoclonal antibody FF-21101 radioimmunotherapy

Akihiro Hino, Masaichi Naruse, Yuuichi Funase, Akio Nagano, Hiroyuki Kasahara, Tadashi Matsuura and Yukio Sudo
Journal of Nuclear Medicine May 2013, 54 (supplement 2) 1367;
Akihiro Hino
1Research Department, FUJIFILM RI Pharma Co., Ltd., Chiba, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Masaichi Naruse
1Research Department, FUJIFILM RI Pharma Co., Ltd., Chiba, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yuuichi Funase
1Research Department, FUJIFILM RI Pharma Co., Ltd., Chiba, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Akio Nagano
1Research Department, FUJIFILM RI Pharma Co., Ltd., Chiba, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hiroyuki Kasahara
1Research Department, FUJIFILM RI Pharma Co., Ltd., Chiba, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tadashi Matsuura
2Perceus Proteomics Inc., Tokyo, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yukio Sudo
2Perceus Proteomics Inc., Tokyo, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
Loading

Article Information

vol. 54 no. supplement 2 1367

Published By 
Society of Nuclear Medicine
Print ISSN 
0161-5505
Online ISSN 
2159-662X
History 
  • Published online November 4, 2014.

Copyright & Usage 
© 2013

Author Information

  1. Akihiro Hino1,
  2. Masaichi Naruse1,
  3. Yuuichi Funase1,
  4. Akio Nagano1,
  5. Hiroyuki Kasahara1,
  6. Tadashi Matsuura2 and
  7. Yukio Sudo2
  1. 1Research Department, FUJIFILM RI Pharma Co., Ltd., Chiba, Japan
  2. 2Perceus Proteomics Inc., Tokyo, Japan

Statistics from Altmetric.com

Cited By...

  • Citations
  • Google Scholar

This article has not yet been cited by articles in journals that are participating in Crossref Cited-by Linking.

Article usage

Article usage: December 2014 to April 2025

AbstractFullPdf
Dec 2014300
Jul 2015200
Sep 2015600
Dec 2015200
Jan 2016100
Feb 2016400
Mar 2016300
Apr 2016200
May 2016200
Jun 2016100
Jul 2016200
Aug 2016300
Sep 2016300
Oct 2016200
Nov 2016400
Dec 20161100
Jan 20171000
Feb 2017400
Mar 2017300
Apr 2017600
May 2017800
Jun 2017400
Jul 20171000
Aug 2017800
Sep 2017400
Oct 20171000
Nov 2017300
Dec 2017500
Jan 2018800
Feb 20181500
Mar 20181000
Apr 2018400
May 2018900
Jun 2018400
Sep 2018900
Oct 2018800
Nov 20181000
Dec 2018800
Jan 2019300
Feb 2019200
Mar 2019400
Apr 20192300
May 2019400
Jun 2019800
Jul 2019500
Aug 20192300
Sep 2019500
Oct 2019700
Nov 2019500
Dec 2019900
Jan 2020300
Feb 2020600
Mar 2020500
Apr 2020400
May 20208300
Jun 20202200
Jul 2020200
Aug 2020800
Sep 2020500
Oct 20201200
Nov 2020300
Dec 2020500
Jan 20211000
Feb 2021700
Mar 2021900
Apr 2021800
May 20211300
Jun 2021600
Jul 2021300
Aug 2021800
Sep 2021700
Oct 2021200
Nov 2021400
Dec 2021600
Jan 2022400
Feb 2022600
Mar 2022200
Apr 2022300
May 2022200
Jun 2022300
Jul 2022300
Aug 2022600
Sep 2022400
Oct 2022200
Nov 2022400
Dec 2022200
Jan 2023100
Feb 2023300
Mar 2023700
Apr 2023200
May 2023800
Jun 2023600
Jul 2023300
Aug 2023700
Sep 2023800
Oct 2023400
Nov 2023400
Dec 2023400
Jan 20241000
Feb 2024400
Mar 2024100
Apr 2024500
May 2024500
Jun 20241200
Jul 20245200
Aug 20244900
Sep 2024800
Oct 2024500
Nov 20241300
Dec 20241100
Jan 2025700
Feb 20251300
Mar 20251900
Apr 20251200
Previous
Back to top

In this issue

Journal of Nuclear Medicine
Vol. 54, Issue supplement 2
May 2013
  • Table of Contents
  • Index by author
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Preclinical evaluation of anti-cadherin 3 human-mouse chimeric monoclonal antibody FF-21101 radioimmunotherapy
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Preclinical evaluation of anti-cadherin 3 human-mouse chimeric monoclonal antibody FF-21101 radioimmunotherapy
Akihiro Hino, Masaichi Naruse, Yuuichi Funase, Akio Nagano, Hiroyuki Kasahara, Tadashi Matsuura, Yukio Sudo
Journal of Nuclear Medicine May 2013, 54 (supplement 2) 1367;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Preclinical evaluation of anti-cadherin 3 human-mouse chimeric monoclonal antibody FF-21101 radioimmunotherapy
Akihiro Hino, Masaichi Naruse, Yuuichi Funase, Akio Nagano, Hiroyuki Kasahara, Tadashi Matsuura, Yukio Sudo
Journal of Nuclear Medicine May 2013, 54 (supplement 2) 1367;
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Info & Metrics

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

Oncology: Basic, Translational & Therapy

  • Physiological distribution of 68Ga-DOTA-TATE: an atlas of standardized uptake values
  • ROC analysis for xSPECT Bone
  • Long-term outcomes of differentiated thyroid cancer with only lung metastasis and the prognostic factors
Show more Oncology: Basic, Translational & Therapy

MTA I: Radiopharmaceutical Therapy Posters

  • The study of using Rhenium-188 liposomal drug and 5-FU in chemoradiotherapy to suppress tumor growth in head and neck squamous cancer
  • Nephro- and hepatotoxicity after radioligand therapy of metastatic castrate-resistant prostate cancer with 177Lu-PSMA-617
  • Imaging and biochemical predictive biomarkers of overall survival and treatment response in patients receiving 223Ra-dichloride treatment in clinical practice
Show more MTA I: Radiopharmaceutical Therapy Posters

Similar Articles

SNMMI

© 2025 SNMMI

Powered by HighWire